Our expertise

Specialized in the treatment of severe respiratory allergies, Stallergenes' goal is to manage patients which are poorly controlled by symptomatic treatments and offer them an effective solution for treating and controlling their disease.

• 1 in 4 people suffer from respiratory allergy¹. In 20 years (1986-2006), respiratory allergies have doubled².
• Over 500 million people in the world have allergic rhinitis³, of whom 15 to 20% suffer from a severe form of the disease ⁴.

The disease is frequently aggravated since over 40% of people with allergic rhinitis develop allergic asthma⁵. As a consequence, respiratory allergies considerably impair the quality of life of patients and have a massive impact on their work and social life.

A biopharmaceutical laboratory specialised in allergen immunotherapy, Stallergenes is now world leader on the sublingual immunotherapy market with average annual growth of 14% since 2000.

Stallergenes' goal is to manage patients suffering from a severe form of respiratory allergy which is poorly controlled by symptomatic treatments and offer them an effective solution for treating and controlling their disease.

Every year, almost 500 000 patients benefit from laboratory treatments, which curb progress of the disease⁶.

Innovation is part of the Stallergenes heritage. To meet the needs of patients, Stallergenes calls on its specific know-how and an unwavering commitment to R&D with over 20% of sales ploughed back in every year.

The group began developing a major therapeutic solution in 1992: treatment by the sublingual route (solutions for application under the tongue).
Today, Stallergenes is pushing ahead once more by proposing an immunotherapy treatment by tablets for facilitated management of patients. Registered as proprietary medicinal products, these treatments represent a new therapeutic class.

A key player on its market, Stallergenes has set itself the goal of working alongside healthcare professionals to advance management of severe respiratory allergies and achieve long-term improvements in quality of life for allergic patients.

¹ Bauchau V. et al. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. Allergy. 2005: 60: 350-353
² Demoly P. Les allergies. Arnaud Franel Éditions, 2001.
³ Bousquet J. et al. Allergic Rhinitis and its Impact on Asthma (ARIA).Allergy. 2008: 63 (Suppl. 86): 8–160
⁴ White P. et al. Symptom control in patients with hay fever in UK general practice: how well are we doing and is there a need for allergen immunotherapy? Clinical. And Experimental  Allergy, 1998; 28:266-270
⁵ Jacobsen L. Allergy 1997;52: 914-20.Moller C. et al. JACI 2002; 109:251-256.
⁶ Bousquet J, Lockey RF, Malling HJ. et al. Allergy 1998; 53